Table 5.
Sensitivity analyses results
| Parameter sensitivity analysis | Treatment group | Cost | Incremental cost (95% confidence interval) | Effectiveness (95% confidence interval) | Incremental effect (95% confidence interval) |
|---|---|---|---|---|---|
| Base Case | |||||
| Maintain | $96,385 ($83,213 to $109,976) | −$46,194 (−$42,420 to −$50,455) | 3.19 (2.47 to 3.83) | −0.13 (−0.16 to −0.07) | |
| Switch | $50,191 ($40,792 to $59,521) | 3.0607 (2.31 to 3.76) | |||
| Reference Infliximab Price | |||||
| 20% Price Reduction in Reference Infliximab Price | Maintain | $80,203 ($68,432 to $92,173) | −$30,011 (−$27,639 to −$32,653) | 3.19 (2.47 to 3.83) | −0.13 (−0.16 to −0.07) |
| Switch | $50,191 ($40,792 to $59,521) | 3.06 (2.31 to 3.76) | |||
| Biosimilar Price | |||||
| Biosimilar Price set at 72% Discount from Reference Infliximab Price | Maintain | $96,385 ($83,213 to $109,976) | −$61,245 (−$56,624 to −$66,335) | 3.19 (2.47 to 3.83) | −0.13 (−0.1604 to −0.0729) |
| Switch | $35,140 ($26,588 to $43,641) | 3.06 (2.31 to 3.76) | |||
| Utility | |||||
| Gregor et al. (1997) Utilities | Maintain | $96,385 ($83,213 to $109,976) | −$46,194 (−$42,420 to −$50,455) | 3.50 (1.49 to 4.95) | −0.16 (−0.24 −0.01) |
| Switch | $50,191 ($40,792 to $59,521) | 3.34 (1.25 to 5.00) | |||
| Biosimilar Relapse Rate | |||||
| Komaki et al. (2017) Relapse Rates | Maintain | $96,426 ($83,370 to $109,959) | −$28,924 (−$26,280 to −$33,213) | 3.19 (2.47 to 3.83) | 0.21 (0.06 to 0.30) |
| Switch | $67,502 ($50,158 to $83,679) | 3.40 (2.53 to 4.13) | |||
| Time Horizon | |||||
| 1 Year | Maintain | $32,334 ($29,403 to $35,264) | −$13,106 (−$13,481 to −$12,778) | 0.84 (0.64 to 1.00) | −0.13 (−0.16 to −0.07) |
| Switch | $19,228 ($15,922 to $22,486) | 0.83 (0.63 to 0.99) | |||
| Time Horizon | |||||
| 10 Years | Maintain | $132,420 ($107,873 to $159,986) | −$67,212 (−$55,688 to −$81,392) | 5.72 (4.27–7.07) | −0.23 (−0.37 to −0.04) |
| Switch | $65,207 ($52,185 to $78,594) | 5.49 (3.91–7.04) |